ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2018

Abstract Number: 2642

Atacicept Dose Rationale for a Phase 3 Study in Patients with High Disease Activity and Auto-Antibody Positive SLE

Jinshan Shen1, Orestis Papasouliotis2, Eileen Samy1, Philipp Haselmayer3, Peter Chang4, Victor Ona1 and Amy H. Kao1, 1EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, 2Merck Institute for Pharmacometrics, an affiliate of Merck KGaA, Darmstadt, Germany, Lausanne, Switzerland, 3Merck KGaA, Darmstadt, Germany, 4EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), BIllerica, MA

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2018

Keywords: APRIL, BLyS, pharmacokinetics, safety and systemic lupus erythematosus (SLE)

Session Information

Date: Tuesday, October 23, 2018

Title: Systemic Lupus Erythematosus – Clinical Poster III: Treatment

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Atacicept targets the B-cell-stimulators BLyS and APRIL, and is in development for the treatment of patients (pts) with SLE. Here, we integrated non-clinical and clinical data to determine an appropriate atacicept dose for a Phase 3 (P3) study in auto-antibody positive SLE pts with high disease activity (HDA).

Methods:

Non-clinical data for atacicept were obtained from two murine models: a spontaneous SLE model (given control or mouse TACI-Fc 5 mg/kg intraperitoneally [IP] 3 times per week [wk]) and a 4-hydroxy-3-nitrophenylacetyl-Keyhole Limpet Haemocyanin (NP-KLH) vaccinated model to assess immunomodulation (given control or atacicept 1, 3 or 10 mg/kg IP every third day). Clinical data were obtained from a P1 pharmacokinetic (PK) study in healthy participants (Study 022; single-dose atacicept 25, 75 or 150 mg) and two P2 studies in pts with autoantibody-positive SLE (APRIL-SLE [NCT00624338]; ADDRESS II [NCT01972568]). In both P2 studies, pts were randomized (1:1:1) to once-wkly (QW; initial 4 wks of twice-weekly dosing in APRIL-SLE) subcutaneous atacicept (75 or 150 mg) or placebo (PBO). Primary endpoints: APRIL-SLE, proportion of pts with BILAG A/B flare over 52 wks; ADDRESS II, SRI-4 response at Wk 24. An analysis of SRI-6 response at Wk 24 was performed in ADDRESS II pts with Screening HDA (SLEDAI-2K≥10). A population PK model was developed and population PK model-derived exposure vs probability of clinical response (BILAG A/B flare, SRI-4, SRI-6) evaluated. An exploratory analysis of the impact of atacicept exposure on safety was also performed.

Results:

In the spontaneous SLE model, TACI-Fc 5 mg/kg prevented proteinuria development and glomerular damage. In atacicept-treated NP‑KLH vaccinated mice, anti-KLH IgG decreased markedly (>50% reduction vs control at all doses), with mean atacicept serum trough concentrations (Cmin) of ~2.3 µg/mL (1 mg/kg), ~5 µg/mL (3 mg/kg) and ~8.5 µg/mL (10 mg/kg). Atacicept 150 mg QW resulted in greater clinical responses than PBO (APRIL-SLE: BILAG A/B flare, time to flare; ADDRESS II: SRI-4 [modified intention-to-treat] and SRI-6 response [HDA]). In both studies, atacicept exposure-response (E-R) relationships were identified. For maximal flare reduction, atacicept AUCτ (area under the concentration curve over one dosing interval, i.e. 1 wk) ≥1 mg∙hr/mL was identified and was more achievable with 150 than 75 mg (60% vs 15% probability); AUCτ was the exposure metric that contributed to the P3 dose selection. Atacicept exposure for maximal flare reduction corresponded to a Cmin of 5 µg/mL which was similar to that observed in the murine models. SRI-4 and SRI-6 (HDA) response rates increased with increasing atacicept AUC within the exposure range observed in ADDRESS II. Atacicept 150 and 75 mg had acceptable safety profiles in SLE pts; there was no apparent E-R relationship for serious infections.

Conclusion: Integrated non-clinical, clinical and E-R data demonstrate an acceptable benefit-risk profile for atacicept in SLE pts with HDA and support the selection of 150 mg QW for P3 studies.


Disclosure: J. Shen, EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), 3; O. Papasouliotis, Merck Institute for Pharmacometrics, Lausanne, Switzerland (an affiliate of Merck KGaA, Darmstadt, Germany), 3; E. Samy, EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), 3; P. Haselmayer, Merck KGaA, Darmstadt, Germany, 3; P. Chang, EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), 3; V. Ona, EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), 3; A. H. Kao, EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), 3.

To cite this abstract in AMA style:

Shen J, Papasouliotis O, Samy E, Haselmayer P, Chang P, Ona V, Kao AH. Atacicept Dose Rationale for a Phase 3 Study in Patients with High Disease Activity and Auto-Antibody Positive SLE [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/atacicept-dose-rationale-for-a-phase-3-study-in-patients-with-high-disease-activity-and-auto-antibody-positive-sle/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/atacicept-dose-rationale-for-a-phase-3-study-in-patients-with-high-disease-activity-and-auto-antibody-positive-sle/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology